Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report)’s share price dropped 5.8% on Tuesday after Truist Financial lowered their price target on the stock from $25.00 to $15.00. Truist ...

Iovance Biotherapeutics (NasdaqGM:IOVA) recently reaffirmed its earnings guidance for 2025 and projected significant revenue growth for 2026, alongside announcing a notable revenue increase in its ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research ...

In a report released today, Peter Lawson from Barclays maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research Report), with a ...

Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Iovance Biotherapeutics in a report issued ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $16.38, a high estimate of $32.00, and a low estimate of $6.00. Highlighting a 10.88% decrease, the current ...

Iovance Biotherapeutics, Inc. sees mixed TIL therapy success with Amtagvi in PD-1-refractory melanoma. Click here to find out ...

Iovance Biotherapeutics Inc (IOVA) reaches revenue targets and plans global expansion, despite facing competition and ...

Iovance Biotherapeutics, Inc.’s IOVA share price has dipped by 19.49%, which has investors questioning if this is right time ...

Although it reported 2024 Q4 and full-year results that beat expectations and reiterated 2025 guidance that includes ...

The commercial-stage biotechnology company posted revenue of $73.7 million for the quarter, missing the consensus estimate of $77.33 million. However, adjusted earnings per share came in at -$0.26, ...

SAN CARLOS, Calif. (AP) — SAN CARLOS, Calif. (AP) — Iovance Biotherapeutics Inc. (IOVA) on Thursday reported a loss of $78.6 million in its fourth quarter. On a per-share basis, the San Carlos, ...